Neuroinflammation in Hypertension Study

The Role of Neuroinflammation in Hypertension.Minocycline for Resistant Hypertension: a Randomized Double Blind Placebo-Controlled Trial

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04478500

Acronym

MINIHT

Enrollment

Registered

2020-07-20

Start date

2020-07-02

Completion date

2025-02-01

Last updated

2022-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant Hypertension

Brief summary

To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.

Detailed description

This is a randomized, double-blind, placebo controlled, parallel group design study aiming to compare the effects of minocycline 100mg twice daily vs matched placebo for 12 weeks on ambulatory BP and the parameters of sympathetic and immune activation

Interventions

DRUGMinocycline

Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo. Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

45 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Aged: 45 -65 years * Signed informed consent * Clinical diagnosis of Resistant Hypertension * Daytime systolic ambulatory BP \>135mmHg.

Exclusion criteria

• eGFR of \<45 mL/min/1.73m2 * History of myocardial infarction (MI) or any cardiovascular event within 3 months of screening period, clinically significant AV conduction disturbances and/or arrhythmias, * current of past history of heart failure (LVEF ≤40%) * psychotropic agents, antidepressants and NSAIDS * alcohol consumption of \>3 standard drinks. * known hypersensitivity or contraindication to minocycline or other tetracyclines.

Design outcomes

Primary

Measure	Time frame	Description
The difference in the daytime systolic blood pressure between groups after respective treatment.	12 weeks	Office and ambulatory blood pressures
Assessment of change in central and peripheral inflammation	12 weeks	FDG PET

Secondary

Measure	Time frame	Description
Change in muscle sympathetic nerve activity	12 weeks	Muscle sympathetic nerve activity assessed by microneurography
Change in central Blood Pressure	12 weeks	central Blood Pressure assessed by Sphygmocor XCEL

Countries

Australia

Contacts

Primary ContactRevathy Carnagarin, MD

revathy.carnagarin@uwa.edu.au+61892240316

Backup ContactOmar Azzam, MD

omar.azzam@health.wa.gov.au+61892242244

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026